Jazz Pharmaceuticals plc (JAZZ)

Market Cap	6.63B
Revenue (ttm)	3.84B
Net Income (ttm)	330.79M
Shares Out	63.06M
EPS (ttm)	4.86
PE Ratio	21.62
Forward PE	5.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	391,701
Open	106.15
Previous Close	106.47
Day's Range	104.48 - 106.53
52-Week Range	103.01 - 146.70
Beta	0.62
Analysts	Buy
Price Target	189.93 (+80.73%)
Earnings Date	Aug 7, 2024

About JAZZ

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2007
• Employees: 2,800
• Stock Exchange: NASDAQ
• Ticker Symbol: JAZZ

Analyst Forecast

According to 16 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $189.93, which is an increase of 80.73% from the latest price.

Price Target

$189.93

(80.73% upside)

Analyst Consensus: Buy